Onderneming Relmada Therapeutics, Inc.
Aandelen
RLMD
US75955J4022
Biotechnologie & Medisch Onderzoek
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
3,7 USD | -4,15% | -13,95% | -10,63% |
Vakgebied
Aantal werknemers: 20
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Paolo Manfredi
FOU | Founder | 62 | 31-05-12 |
Sergio Traversa
CEO | Chief Executive Officer | 63 | - |
Maged Shenouda
DFI | Director of Finance/CFO | 59 | 12-11-15 |
Charles Ence
CMP | Compliance Officer | 64 | 29-07-19 |
John Hixon
PRN | Corporate Officer/Principal | - | 21-07-22 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chairman | 78 | 14-07-15 | |
Sergio Traversa
CEO | Chief Executive Officer | 63 | - |
Maged Shenouda
DFI | Director of Finance/CFO | 59 | 12-11-15 |
Fabiana Fedeli
BRD | Director/Board Member | 53 | 12-01-23 |
Director/Board Member | 62 | 19-12-19 | |
Paul Kelly
BRD | Director/Board Member | 65 | 12-11-15 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 30 174 202 | 27 748 959 ( 91,96 %) | 0 | 91,96 % |
Bedrijfsgegevens
Relmada Therapeutics, Inc.
2222 Ponce de Leon Boulevard 3rd floor
33134, Coral Gables
+786-629-1376
http://www.relmada.comSector
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-10,63% | 112 mln. | |
-2,26% | 103 mld. | |
+1,41% | 95,71 mld. | |
+0,79% | 22,02 mld. | |
-17,84% | 20,9 mld. | |
-11,11% | 17,85 mld. | |
-42,83% | 16,21 mld. | |
-17,63% | 15,52 mld. | |
+4,55% | 13,86 mld. | |
+32,11% | 12,04 mld. |
- Beurs
- Aandelen
- Koers RLMD
- Onderneming Relmada Therapeutics, Inc.